63 research outputs found
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours
The ether lipid miltefosine (hexadecylphosphocholine) was orally given to patients with various tumours in a dose-finding study. All patients initially received a daily total dose of 100 mg, which in the absence of side-effects was increased to 150 mg and further to 200 mg. A total of 54 patients were entered and were evaluable for gastrointestinal toxicity. Nausea and vomiting were found to be dose-limiting; 22% of patients ultimately tolerated a dose of 100 mg, 59% tolerated a dose of 150 mg and 19% tolerated a dose of 200 mg. In addition 30% of patients developed renal dysfunction, which was thought to be related to the drug. No other toxities were observed. For further phase II studies it is recommended that one starts with a dose of 150 mg daily, divided over three administrations
The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo
Peripheral neuropathy is an important and disabling side-effect of cisplatin treatment. A new drug, Org 2766, has been found to prevent this neuropathy up to 1 month after treatment. A group of 18 patients with ovarian cancer, who participated in an earlier randomized study with placebo or Org 2766, together with cisplatin and cyclophophamide, were thereafter prospectively followed up to 2 years after discontinuation of treatment to monitor the development of neurological signs and symptoms and vibration perception threshold (VPT). Exploratory, descriptive data analysis shows that between 1 and 4 months after the last cycle the average sum score for neurological signs and symptoms and VPT had deteriorated compared with 1 month after treatment. Thereafter a gradual but incomplete improvement was seen between 4-12 and 12-24 months after treatment. These changes were seen in all patients regardless of previous treatment with Org 2766 or placebo, but deterioration was less pronounced in patients previously treated with Org 2766. These results suggests that treatment with Org 2766 to prevent a cisplatin-induced neuropathy should possibly be continued up to 4 months after the last cycle of cisplatin
Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: A phase II study
The efficacy of Org 2766, an ACTH(4–9) analogue, on the recovery of cisplatin neuropathy of longstanding duration was investigated in a phase II study. Twenty-two patients were treated with Org 2766 during a period of 4 months and vibration perception threshold (VPT) and sum scores for neuropathic symptoms and signs were compared with pre-treatment values. No change in VPT could be detected. Although there was a small improvement of clinical measures for neuropathy, no clear evidence for repair could be obtained. These results indicate no beneficial effect of Org 2766 on recovery of a longstanding cisplatin neuropathy
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
This Phase I study was performed to assess the feasibility of combining
docetaxel with the new P-glycoprotein inhibitor R101933 and to determine
the dose limiting toxicity of this combination. Fifteen patients received
oral R101933 alone at a dose escalated from 200 to 300 mg twice daily
(b.i.d.; cycle 0), an escalating i.v. dose of docetaxel (60, 75, and 100
mg/m2) as a 1-h infusion (cycle 1), and the combination (cycle 2 and
further). Dose limiting toxicity consisting of mucositis and neutropenic
fever was reached at the combination of docetaxel, 100 mg/m2, and R101933,
300 mg b.i.d., and the maximum tolerated dose was established at
docetaxel, 100 mg/m2, and R101933, 200 mg b.i.d. Plasma concentrations of
R101933 achieved in patients were in the same range as required in
preclinical rodent models to overcome paclitaxel resistance. The plasma
pharmacokinetics of docetaxel were not influenced by the R101933 regimen
at any dose level tested, as indicated by plasma clearance values of 26.5
+/- 7.78 liters/h/m2 and 23.4 +/- 4.52 liters/h/m2 (P = 0.15) in cycles 1
and 2, respectively. These findings indicate that the contribution of a
P-glycoprotein inhibitor to the activity of anticancer chemotherapy can
now be assessed in patients for the first time independent of its effect
on drug pharmacokinetics
Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer
Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus
BACKGROUND: We have previously reported a favourable response rate in
patients with advanced esophageal cancer after treatment with a biweekly
regimen of paclitaxel and cisplatin. In this study we investigate the
feasibility and efficacy of this regimen in a neo-adjuvant setting.
PATIENTS AND METHODS: Patients with resectable squamous cell carcinoma of
the esophagus received paclit-axel 180 mg/m(2) and cisplatin 60 mg/m(2)
every 2 weeks. Patients received three courses and responding patients
received three additional courses; thereafter, patients were referred for
surgery. Patient characteristics of 50 eligible patients were as follows:
male, 60%; median age, 62 years (range 45-78); median World Health
Organization performance status of 1 (range 0-2). RESULTS: Ninety-four per
cent of patients received at least three courses of chemotherapy.
Haematological toxicity consisted of National Cancer Institute-Common
Toxicity Criteria grade 3 or 4 neutropenia in 71% of patients, with
neutropenic fever occurring in only two patients (4%). The overall
response rate was 59%. Pathological examination showed tumour-free margins
in 38 patients. In seven patients no residual tumour was found. The median
overall survival was 20 months and the 1- and 3-year survival rates were
68% and 30%, respectively. CONCLUSIONS: This dose-dense schedule of
paclitaxel and cisplatin administered biweekly is well tolerated and the
observed overall and complete response rates are promising
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer
As a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore high-dose-intensity regimens in non-small-cell lung cancer. In a phase I study of weekly administration of cisplatin combined with oral etoposide we achieved a cisplatin dose intensity of 52.5-60 mg/m2 per week in most patients. We subsequently explored this regimen in advanced non-small-cell lung cancer. Patients were treated with cisplatin infused at 70 mg/m2 on days 1, 8, 15 and 29, 36, 43 in combination with oral etoposide given at 50 mg on days 1-15 and 29-43. Patients showing stable disease or a better response were continued on treatment with oral etoposide given at 50 mg/m2 per day on days 1-21 every 28 days for a maximum of four cycles. In all, 22 patients with stage III disease and 31 patients with stage IV disease entered the study. The median number of cisplatin administration was 6 per patient; 17 patients reached the planned cisplatin dose intensity of 60 mg/m2 per week, 11 patients achieved 52.5 mg/m2 per week, and 7 patients reached 47 mg/m2 per week. Overall, 11 of 21 stage III patients had a partial response [response rate 51%, 95% confidence interval (CI) 36-81%], as did 9 of 28 patients with stage IV disease (32%; 95% CI 15-49%). Toxicity was mainly hematologic, with leukocytopenia being the most frequent cause of treatment delay. Nephrotoxicity of grade 1 was observed in seven patients. Two patients developed clinical hearing loss. With this schedule a high median cisplatin dose intensity of 52.5-60 mg/m2 per week was reached. The 51% response rate achieved in stage III disease makes this schedule attractive for further exploration; however, it is not recommended for routine use in stage IV disease
Phase II study of weekly 4′-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC gynaecological cancer cooperative group study
Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study
Epidermal growth factor receptor (EGF-R) was studied with monoclonal antibody 2E9 on 50 ovarian tumors of various histological types and 10 non-tumorous ovarian tissues by immunohistochemistry. Enhanced expression was observed in 26/50 (52%) of the tumors. Only 25 out of 46 epithelial tumors (54%) showed positivity in epithelial tumor cells. Staining was cytoplasmic in all cases. No correlation was established between EGF-R expression and the histological type of the epithelial tumor. Apart from EGF-R expression in tumor cells, low immunoreactivity was also observed in stromal and endothelial cells in both normal and tumorous ovarian tissues. Furthermore in 8/9 specimens containing necrotic areas, EGF-R was noticed in these areas as well. Both of the latter observations may have impact on the evaluation of the prognostic value of EGF-R activity in tumors, when based on EGF-R measurements using biochemical binding studies. We therefore recommend that EGF-R is measured with both methods in studies regarding its clinical value
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma
The results of cytostatic therapy in metastatic melanoma are very disappointing. In phase II studies with high-dose cisplatin regimens, a remarkably high response rate was observed. In a phase I study with a short course of weekly cisplatin, combined with oral etoposide, we were able to reach, in most patients, a cisplatin dose intensity of 60 mg/m2/week. We performed a phase II study with this schedule in metastatic malignant melanoma. 15 consecutive patients were entered in the study. Treatment consisted of cisplatin 70 mg/m2 on days 1, 8, 15 and days 29, 36, 43 combined with oral etoposide 50 mg daily, days 1-15 and days 29-43. Patients with a response or stable disease continued treatment with oral etoposide 50 mg/m2 daily, days 1-21 every 4 weeks. All patients were evaluable for response and toxicity. The majority of the patients received six cycles of cisplatin with the planned cisplatin dose intensity of 60 mg/m2/week. A partial response was observed in 2 patients (13%; 95% confidence interval (CI) 2-44%) of, respectively, 22 and 12 weeks; stable disease was observed in 6 patients. Toxicity consisted mainly of alopecia and bone marrow suppression. 4 patients had tinnitus, one patient had neurotoxicity grade 1. The regimen studied has only limited activity in metastatic melanoma in spite of the high-dose intensity of cisplatin reached with this schedule
- …